Internet Archive Scholar

Characterizing genetic variants for clinical action

Erin M. Ramos, Corina Din-Lovinescu, Jonathan S. Berg, Lisa D. Brooks, Audrey Duncanson, Michael Dunn, Peter Good, Tim J.P. Hubbard, Gail P. Jarvik, Christopher O'Donnell, Stephen T. Sherry, Naomi Aronson (+23 others)
2014 American Journal of Medical Genetics. Part C, Seminars in Medical Genetics  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (202.1 kB)
https://web.archive.org/web/20200206024403/http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4158437&blobtype=pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

Genome-wide association studies, DNA sequencing studies, and other genomic studies are finding an increasing number of genetic variants associated with clinical phenotypes that may be useful in developing diagnostic, preventive, and treatment strategies for individual patients. However, few common variants have been integrated into routine clinical practice. The reasons for this are several, but two of the most significant are limited evidence about the clinical implications of the variants and
more » ... a lack of a comprehensive knowledge base that captures genetic variants, their phenotypic associations, and other pertinent phenotypic information that is openly accessible to clinical groups attempting to interpret sequencing data. As the field of medicine begins to incorporate genome-scale analysis into clinical care, approaches need to be developed for collecting and characterizing data on the clinical implications of variants, developing consensus on their actionability, and making this information available for clinical use. The National Human Genome Research Institute (NHGRI) and the Wellcome Trust thus convened a workshop to consider the processes and resources needed to: 1) identify clinically valid genetic variants; 2) decide whether they are actionable and what the action should be; and 3) provide this information for clinical use. This commentary outlines the key discussion points and recommendations from the workshop.
doi:10.1002/ajmg.c.31386 pmid:24634402 pmcid:PMC4158437 fatcat:gebtnuuwljdoxnb5dtrkbmauda
Citation

Erin M. Ramos, Corina Din-Lovinescu, Jonathan S. Berg, Lisa D. Brooks, Audrey Duncanson, Michael Dunn, Peter Good, Tim J.P. Hubbard, Gail P. Jarvik, Christopher O'Donnell, Stephen T. Sherry, Naomi Aronson, Leslie G. Biesecker, Bruce Blumberg, Ned Calonge, Helen M. Colhoun, Robert S. Epstein, Paul Flicek, Erynn S. Gordon, Eric D. Green, Robert C. Green, Matthew Hurles, Kensaku Kawamoto, William Knaus, David H. Ledbetter, Howard P. Levy, Elaine Lyon, Donna Maglott, Howard L. McLeod, Nazneen Rahman, Gurvaneet Randhawa, Catherine Wicklund, Teri A. Manolio, Rex L. Chisholm, Marc S. Williams. "Characterizing genetic variants for clinical action." American Journal of Medical Genetics. Part C, Seminars in Medical Genetics 166.1 (2014) 93-104